Kyverna Therapeutics (KYTX) Share-based Compensation (2023 - 2026)

Kyverna Therapeutics (KYTX) has 4 years of Share-based Compensation data on file, last reported at $3.2 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 46.74% year-over-year to $3.2 million; the trailing twelve-month figure through Mar 2026 stood at $11.1 million (up 34.59% YoY), and the FY2025 full-year result was $10.1 million, up 20.62% from the prior year.
• Share-based Compensation for Q1 2026 stood at $3.2 million, up from $2.7 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $3.4 million in Q3 2024 and bottomed at $446000.0 in Q2 2023.
• The 4-year median for Share-based Compensation is $2.2 million (2025), against an average of $1.8 million.
• The widest annual swing landed in 2024, when Share-based Compensation jumped 555.09%; it then fell 20.92% in 2025.
• A 4-year view of Share-based Compensation shows it stood at $784000.0 in 2023, then soared by 76.28% to $1.4 million in 2024, then jumped by 95.51% to $2.7 million in 2025, then increased by 17.36% to $3.2 million in 2026.
• The last three Share-based Compensation figures came in at $3.2 million (Q1 2026), $2.7 million (Q4 2025), and $2.7 million (Q3 2025), per Business Quant data.

Peer Comparison